Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

NCT00877006 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

447

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: bendamustine
DRUG: rituximab
DRUG: vincristine
DRUG: prednisone
DRUG: cyclophosphamide
DRUG: doxorubicin

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.